Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative

Pacira BioSciences (PCRX) just wrapped up FY 2025 with Q4 revenue of US$196.9 million and basic EPS of US$0.04, alongside trailing twelve month revenue of US$726.4 million and basic EPS of US$0.16. Over recent quarters, revenue has moved from US$168.9 million in Q1 2025 to US$196.9 million in Q4 2025, while quarterly EPS has ranged from a loss of US$0.11 in Q2 2025 to a profit of US$0.12 in Q3 2025 and US$0.04 in the latest quarter. This sets up a narrative that combines a return to profitability with tight, closely watched margins.

See our full analysis for Pacira BioSciences.

With the headline numbers on the table, the next step is to consider how this shift in profitability and margin profile aligns with the current narratives around Pacira’s long-term earnings power and risk profile.

See what the community is saying about Pacira BioSciences

NasdaqGS:PCRX Revenue & Expenses Breakdown as at Feb 2026 Profitability Returns After Multi Year Decline On a trailing 12 month basis, Pacira reported US$7.0 million of net income and basic EPS of US$0.16 after several years where earnings declined by 59.5% per year over five years. What stands out to bullish investors is that this move back into profit, even at a modest level, aligns with their view that payer adoption and partnerships can support longer term earnings growth. However, the sharp multi year earnings decline in the recent past shows that execution and demand have not been consistently smooth.
Supporters point to recent profitability as evidence that margin work and product uptake are gaining traction, while the five year earnings decline rate highlights how sensitive results have been when volumes or costs move in an unfavorable direction. This mix, a small profit today against a history of sizable losses, is what bulls see as the starting point for further improvement and what more cautious investors see as a reminder that the turnaround is still early. Pacira’s recent swing back into profit has bulls arguing this is the early stage of a longer earnings rebuild, while skeptics point to the five year decline as a warning that the recovery may not be straightforward. 🐂 Pacira BioSciences Bull Case High 134x P/E Versus Industry The trailing P/E multiple is 134x, compared with about 19.9x for the US pharmaceuticals industry and 17.1x for peers, so the shares are currently priced on earnings at a much richer level than many comparables. Bears argue that this high multiple, on only US$0.16 of trailing EPS, leaves little room for disappointment and reflects a lot of optimism. They contrast it with the company’s five year earnings decline of 59.5% per year and revenue growth that is reported at 5.8% per year, below the 10.3% rate cited for the broader US market.
Critics highlight that when a business with modest trailing revenue growth and a history of earnings contraction trades at a 134x P/E, investors are effectively paying a premium price ahead of more proof that profits can build from here. This cautious view leans heavily on the idea that if revenue growth continues to trail the broader market and margins do not strengthen meaningfully, it becomes harder to justify such a large premium to the industry multiple. Skeptical investors look at a 134x P/E on modest recent profits and ask whether the numbers really support the price bulls are willing to pay. 🐻 Pacira BioSciences Bear Case DCF Fair Value Versus US$21.91 Price The provided DCF fair value of US$107.08 is very large compared with the current share price of US$21.91, which implies the stock trades about 79.5% below that DCF estimate even though trailing revenue growth is 5.8% per year and the company has only recently returned to a small profit. Consensus narrative notes that this kind of valuation gap, alongside forecasts that revenue could grow at 5.8% per year versus a 10.3% US market rate, creates a split view where some investors focus on the cash flow based upside while others focus on the slower growth profile and prior multi year earnings decline.
For investors who lean toward the consensus view, the combination of a high trailing P/E and a DCF fair value far above the market price underscores how sensitive any valuation case is to assumptions about future margins and growth rather than what the recent US$7.0 million of net income alone would justify. At the same time, the contrast between the DCF fair value and the US$21.91 price highlights why analyst targets such as US$29.00 can sit between those two anchors, reflecting both the potential in the cash flow model and the reality of the current growth and earnings track record. Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Pacira BioSciences on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

After weighing the mixed signals around Pacira, do you feel the story tilts more toward risk or opportunity, and are you ready to test that view against the numbers yourself? To round out your thinking, it is worth checking where the balance of concerns and potential upside currently sits through 2 key rewards and 1 important warning sign

See What Else Is Out There

Pacira combines a very high 134x P/E, a history of multi year earnings decline and revenue growth that trails the broader US market, which leaves limited room for setbacks.

If that mix feels too costly for your comfort, compare it with 49 high quality undervalued stocks today so you can focus on companies where the price more clearly matches the fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com